Return of Unused and Expired COVID-19 XBB Vaccine Doses (PDF, en anglais seulement)

Registration for the 2024/25 Vaccine Preventable Respiratory Illnesses Immunization Program (PDF, en anglais seulement)

COVID & Flu Order Survey is scheduled to close on April 30th at midnight (PDF, en anglais seulement)

Increasing Vaccine Uptake for 2023 Influenza and COVID-19 Immunization Program (PDF, en anglais seulement)

Novavax XBB.1.5 COVID-19 Vaccine Availability, Collaborative Vaccine Redistribution and Updated Respiratory Illness Screening Resources (PDF, en anglais seulement)

Pfizer XBB.1.5 Tariff Codes (PDF, en anglais seulement)

Harmonization of COVID-19 Vaccine Administrative Process (PDF, en anglais seulement)

Recommendation for the use of the updated XBB.1.5 formulation for fall 2023 and returning unused COVID-19 vaccines (PDF, en anglais seulement)

Manitoba's Influenza & COVID-19 Immunization Program Update for Pharmacists (pdf, en anglais seulement)

2023/24 COVID-19 and Influenza Immunization Program Registration is Open (PDF, en anglais seulement)

COVID-19 Janssen (JCOVDEN™) Vaccine Discontinuation in Canada Effective June 30, 2023 (PDF, en anglais seulement)

COVID-19 Bivalent Vaccines Recommended for Primary Series Use (PDF, en anglais seulement)

SPRING CLEANING - VACCINE RETURNS (PDF, en anglais seulement)

Moderna Product Updates (PDF, en anglais seulement)

COVID-19 Spring Booster Recommendations (PDF, en anglais seulement)

Shelf-Life Extension for Moderna Monovalent COVID-19 Vaccines and Discontinuation of Moderna Infant COVID-19 Vaccine  (PDF, en anglais seulement)

Shelf-Life Extension for Tromethamine-Containing Pfizer Monovalent Vaccines from 12 Months to 18 Months (PDF, en anglais seulement)

Pfizer Pediatric BA.4/5 Bivalent COVID-19 Vaccine for 5 to 11 year olds (PDF, en anglais seulement)

Updated Clinical Recommendations on Concurrent Administration of Vaccines for Children 6 months to 4 years old and Management of Radiocontrast Allergies and COVID-19 Vaccine Administration (PDF, en anglais seulement)

Replacement of Expiring COVID-19 Vaccine: Pfizer/Comirnaty™ Monovalent 30mcg Product (Purple cap) with Pfizer/Comirnaty™ Monovalent 30mcg Product (Grey cap) (PDF, en anglais seulement)

COVID-19 Vaccine: Prioritization of Moderna/Spikevax™ Infant Pediatric for second doses and primary series of immunocompromised children aged 6 months to ≤ 4 years (PDF, en anglais seulement)

Recommendations for COVID-19 Vaccine Booster Doses for Pregnant and Breastfeeding Individuals (PDF, en anglais seulement)

COVID-19 Vaccine: Approval of Pfizer/Comirnaty™ Infant Pediatric and guidance for children aged 6 months to ≤ 4 years (PDF, en anglais seulement)

Bivalent COVID-19 Vaccine: Approval, Eligibility and Guidance (PDF, en anglais seulement)

Bivalent COVID-19 Vaccine: Expanded Eligibility (PDF, en anglais seulement)

Bivalent COVID-19 Vaccine: Approval, Eligibility and Guidance (PDF, en anglais seulement)

COVID-19 Vaccine: Approval & Eligibility on a First Booster Dose for Children aged 5 to 11 years (PDF, en anglais seulement)

COVID-19: Communication to Providers Regarding Booster Doses  (PDF, en anglais seulement)

COVID-19 Vaccine: approval/guidance for children aged 6 months to ≤ 4 years (PDF, en anglais seulement)

COVID-19 Vaccine: Updated Interval for Booster Doses and Expanded Eligibility for Second Booster Doses (PDF, en anglais seulement)

Manitoba COVID-19 Vaccine: Novavax, 12-17 year old and 18+ First Boosters (PDF, en anglais seulement)

Manitoba COVID-19 Vaccine: Second Booster Recommendations and Moderna for 6-11 years of age (PDF, en anglais seulement)

COVID-19 Vaccine: mRNA vaccine supply update and updated interchangeability guidance for individuals aged ≥ 30 years (PDF, en anglais seulement)

COVID-19 Vaccine: Booster Dose Guidance for Adolescents (PDF, en anglais seulement)

COVID-19 Vaccine: Clarifying Recommended and Minimum Intervals (PDF, en anglais seulement)

COVID-19 Vaccine: Moderna for individuals aged ≥ 30 years (PDF, en anglais seulement)

COVID-19 Vaccine: updated third/booster dose interval for individuals aged ≥ 50 years and updated vaccine product for individuals aged ≥ 30 years(PDF, en anglais seulement)

COVID-19 Vaccine: updated third/booster dose guidance and preferential use of Pfizer/Comirnaty™ for 12 to 29 year olds (PDF, en anglais seulement)

COVID-19 Vaccine: Approval/Guidance for Children aged five to ≤ 11 years (PDF, en anglais seulement)

COVID-19 Vaccine Update: Pharmacists to Start Administering COVID-19 and Influenza Vaccines to Those Five Years of Age and Older (PDF, en anglais seulement)

COVID-19 Vaccine Update: Expanded Third/ Booster Dose 6 Months After Dose 2 Guidance (PDF, en anglais seulement)

COVID-19 Vaccine: Third/Booster Dose Update (PDF, en anglais seulement)

COVID-19 Vaccine RE: Important Program Updates (PDF, en anglais seulement)

COVID-19 Vaccine: Booster/Third Dose Guidance and Expansion to Include Residents of Congregate Elderly Person Housing Sites (PDF, en anglais seulement)

Moderna/Spikevax - Prolongation de 2 mois de la durée de vie (pdf)

COVID-19 Vaccine Medical Exemption Program (PDF, en anglais seulement)

COVID-19 Vaccine: Expansion of Third Doses to Health Care Personnel and to People who received a Viral Vector Vaccine Series (PDF, en anglais seulement)

Manitoba Adopting National Advisory Committee on Immunization (NACI) Guidance (PDF, en anglais seulement)

COVID-19 Vaccine Guidance for Personal Care Homes: Recommended Interval between Second and Third Doses of COVID-19 Vaccine & Update on COVID-19/Flu Vaccine Sequence of Administration(PDF, en anglais seulement)

COVID-19 Vaccine: Additional mRNA Vaccine Dose for Certain Populations and Medical Exemption Program (PDF, en anglais seulement)

COVID-19 Vaccine Guidance for Personal Care Homes: Recommended Interval between Second and Third Doses of COVID-19 Vaccine & Update on COVID-19/Flu Vaccine Sequence of Administration (PDF, en anglais seulement)

COVID-19 Vaccine: Expansion of Third Doses to Personal Care Homes (PDF, en anglais seulement)

COVID-19 Vaccine: Additional Information on Third Doses (PDF, en anglais seulement)

Pfizer - élargissement des conditions approuvées de conservation à ultra-basse température (pdf)

COVID-19 Vaccine: UPDATE - Allergy Assessment and Referral Update (PDF, en anglais seulement)

COVID-19 Vaccine: Allergy Assessment and Referral (PDF, en anglais seulement)

Employee Under Investigation and Case Summary Template (EUICS) Guideline (PDF, en anglais seulement)

Employee Under Investigation and Case Summary Template (EUICS) Guideline (xlsx, en anglais seulement)

Manitoba COVID-19 Vaccine: Clinical Practice Guidelines for Immunizers and Health Care Providers (PDF, en anglais seulement)

COVID-19 Vaccine: New/Updated Communications Products including Clinical Practice Guidelines and Consent Form (PDF, en anglais seulement)

IMPORTANT NOTICE: Effective immediately, pause use of AstraZeneca / COVISHIELD in People aged < 55 years (PDF, en anglais seulement)

First Nations Identification for the Purpose of Booking AstraZeneca/ Covishield Vaccination (PDF, en anglais seulement)

Manitoba COVID-19 Vaccine: Updated AstraZeneca and COVISHIELD Product Monographs and Health Product Risk Communication(PDF, en anglais seulement)

Health Product Risk Communication: Important Safety Information on AstraZeneca and COVISHIELD Vaccines(PDF, en anglais seulement)

COVID-19 Vaccine: New/Updated Communications Products including Clinical Practice Guidelines and Consent Form(PDF, en anglais seulement)

COVID-19 Vaccine: Guidance for Immunizers to Select the Reason for Immunization (PDF, en anglais seulement)

Memo to Health Care Providers on Enhanced Consent (PDF, en anglais seulement)

Pfizer BioNTech - en anglais seulement

CanVax: COVID-19 Vaccine Questions and Answers for Healthcare Providers en anglais seulement

Note aux travailleurs de la santé (PDF, en anglais seulement)